U.S. FDA Approves Expanded Age Indication For GSK's AREXVY, The First Respiratory Syncytial Virus Vaccine For Adults Aged 50-59 At Increased Risk
Portfolio Pulse from Benzinga Newsdesk
The U.S. FDA has approved GSK's AREXVY vaccine for preventing RSV lower respiratory tract disease in adults aged 50-59 who are at increased risk. This expands the vaccine's previous approval for adults aged 60 and older.
June 07, 2024 | 11:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The FDA's approval of GSK's AREXVY for adults aged 50-59 at increased risk of severe RSV outcomes expands the market for this vaccine. This could lead to increased sales and revenue for GSK.
The expanded age indication for AREXVY increases the potential market size for GSK's vaccine, likely leading to higher sales and revenue. This is a positive development for GSK's financial performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100